Tirzepatide
Description
Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.
Documents
DMF + FDA EIR
- CAS: 2023788-19-2
- MF: C225H348N48O68
- MW: 4813.527
- Purity: 98%
- Solubility: Soluble in DMSO Appearance: Whitepowder
- Storage Temp: -20℃ ± 5℃ Indication: Type II diabetes